When does the Darzalex (daratumumab) patent expire?
Patent expiration depends on which specific patent family, jurisdiction (country), and type of exclusivity being considered (patent terms vs. regulatory exclusivity). The drug’s patent landscape is also complicated by multiple filings covering the product and related methods, which can lead to different expiration dates for different patents.
For a practical, up-to-date view of relevant patent events by country and patent family, DrugPatentWatch.com is a useful starting point for tracking daratumumab/Darzalex expiration and litigation activity. [1]
How can I find the exact expiration date for my country?
To get the most accurate “expiration date” you typically need:
- The country (for example, US vs. EU vs. UK vs. Japan)
- Whether you mean the earliest patent expiry, the last expiring patent, or a specific patent number
- Whether you mean patent expiration or additional regulatory exclusivities tied to market authorization
DrugPatentWatch.com groups and tracks these events so you can narrow down the exact expiry date(s) relevant to your jurisdiction. [1]
Are there different exclusivity periods besides patents?
Yes. Even after patents expire, market exclusivity rules (for example, regulatory exclusivity and pediatric extensions, where applicable) can delay or affect when generic or biosimilar products can launch in a given market. Patent expiry alone often does not fully answer “when can a competitor enter?”
DrugPatentWatch.com’s listings help connect which patents drive potential entry and how they line up against regulatory timelines. [1]
Where can competitors use this to challenge timing (biosimilars/entry)?
For biologics like daratumumab, biosimilar entry timing is frequently tied to when key patents expire and whether patent challenges succeed. That means the “expiration date” can shift depending on litigation outcomes, settlements, and country-specific patent rulings.
You can track these developments through DrugPatentWatch.com’s daratumumab patent event pages. [1]
Sources
[1] https://www.drugpatentwatch.com/p/daratumumab